Corestemchemon Inc
166480
Company Profile
Business description
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
Contact
Pangyo 255 beongil 24 I & C Building, 2nd Floor
yeonggi-do, Bundang-gu
Seongnam
Seoul13486
KORT: +82 24973711
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
371
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,637.80 | 12.90 | 0.15% |
| CAC 40 | 7,787.54 | 0.56 | -0.01% |
| DAX 40 | 23,939.18 | 99.01 | -0.41% |
| Dow JONES (US) | 42,073.43 | 25.27 | -0.06% |
| FTSE 100 | 8,722.35 | 3.66 | -0.04% |
| HKSE | 23,573.38 | 315.07 | 1.35% |
| NASDAQ | 19,178.53 | 77.60 | 0.41% |
| Nikkei 225 | 38,432.98 | 710.58 | 1.88% |
| NZX 50 Index | 12,281.31 | 80.95 | -0.65% |
| S&P 500 | 5,902.73 | 14.18 | 0.24% |
| S&P/ASX 200 | 8,409.80 | 12.90 | 0.15% |
| SSE Composite Index | 3,363.45 | 23.51 | 0.70% |